Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183232 | 0.90 | ALDH1A1 (0.45) | MCL1LMNAATMMAPTALDH1A1 | |
| SCHEMBL14895499 | 0.88 | ECE1 (0.35) | MCL1LMNAATMMAPTALDH1A1 | |
| SCHEMBL13785286 | 0.87 | — | — | |
| SCHEMBL8564993 | 0.87 | — | — | |
| SCHEMBL6879131 | 0.87 | — | — | |
| SCHEMBL10117376 | 0.86 | TSHR (0.39) | MCL1LMNAATMMAPTALDH1A1 | |
| SCHEMBL1709120 | 0.86 | MCL1 (0.32) | MCL1LMNAATMMAPTALDH1A1 | |
| SCHEMBL15145452 | 0.85 | MMP2 (0.40) | MCL1LMNAMAPTALDH1A1TDP1 | |
| SCHEMBL20734740 | 0.85 | — | — | |
| SCHEMBL14532758 | 0.85 | MMP2 (0.40) | MCL1LMNAMAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778573-A1 | COMPOUND WITH ANTICANCER ACTIVITY | Kyowa Kirin Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019189778-A1 | COMPOUND WITH ANTICANCER ACTIVITY | 協和発酵キリン株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014142255-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2014-09-18 | — | — | WO | disclosed |
| US-8383745-B2 | Method for producing N-methyl-N-vinylacetamide having improved stability and polymerizability | SHOWA DENKO K.K. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100280204-A1 | METHOD FOR PRODUCING N-METHYL-N-VINYLACETAMIDE HAVING IMPROVED STABILITY AND POLYMERIZABILITY | SHOWA DENKO K.K. (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2239250-A1 | METHOD FOR PRODUCING N-METHYL-N-VINYLACETAMIDE HAVING IMPROVED STABILITY AND POLYMERIZABILITY | Showa Denko K.K. (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | IAPP, GCG, INSR | MCL1 2297/4885LMNA 1369/4885ATM 4843/4885 |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | MCL1 2629/4885LMNA 4161/4885ATM 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.